Quince Sells AIDE/eDSP Assets for $450K, Finalizes President's $1M Severance
QNCX sits 89% above its 52-week low of $15.1.
Summary
Quince Therapeutics sold its AIDE/eDSP technology and Italian subsidiary for $450K and finalized a $1.01M severance for its departing President, as the company continues to address going-concern and Nasdaq listing challenges.
Key Events · M&A and Partnerships · QNCX
-
Asset Sale Completed
Sold Quince SpA equity, AIDE/eDSP IP, and Systems to Ayma Therapeutics for $450,000 cash on September 8, 2026.
-
Pro Forma Gain
Transaction generates a preliminary pro forma gain on sale of subsidiary of $1.749 million, subject to finalization in Q3 2026.
-
President Severance Finalized
Charles Ryan's separation agreement provides $1,014,489.04 in severance: 18 months base salary, 150% pro-rated 2026 bonus, and 18 months COBRA premiums.
-
Going Concern Context
Divestiture follows Q2 2026 going-concern disclosure and Nasdaq delisting notice for $35.3M negative stockholders' equity; $450K proceeds are modest relative to cash needs.
Analysis · QNCX · Life Sciences
Quince Therapeutics completed the sale of its Italian subsidiary and AIDE/eDSP technology assets to Ayma Therapeutics for $450,000 in cash, generating a pro forma gain of $1.75 million. The company also finalized a $1.01 million severance package for departing President Charles Ryan. Against a backdrop of going-concern doubts and a Nasdaq delisting notice for negative equity, this divestiture sheds non-core assets and reduces operating expenses, but the modest proceeds do little to address the company's $35.3 million stockholders' deficit or its cash settlement obligations on Series C Preferred Stock.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $28.59 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $29.1M. The 52-week trading range was $15.10 to $909.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.